Literature DB >> 35705523

Socioeconomic determinants of respiratory health in patients with cystic fibrosis: implications for treatment strategies.

Gabriela R Oates1, Michael S Schechter2.   

Abstract

INTRODUCTION: Great variation exists in the progression and outcomes of cystic fibrosis (CF) lung disease, due to both genetic and environmental influences. Social determinants mediate environmental exposures and treatment success; people with CF from socioeconomically disadvantaged backgrounds have worse health and die younger than those in more advantaged positions. AREAS COVERED: This paper reviews the literature on the mechanisms that are responsible for generating and sustaining disparities in CF health, and the ways by which social determinants translate into health advantages or disadvantages in people with CF. The authors make recommendations for addressing social risk factors in CF clinical practice. EXPERT OPINION: Socioeconomic factors are not dichotomous and their impact is felt at every step of the social ladder. CF care programs need to adopt a systematic protocol to screen for health-related social risk factors, and then connect patients to available resources to meet individual needs. Considerations such as daycare, schooling options, living and working conditions, and opportunities for physical exercise and recreation as well as promotion of self-efficacy are often overlooked. In addition, advocacy for changes in public policies on health insurance, environmental regulations, social welfare, and education would all help address the root causes of CF health inequities.

Entities:  

Keywords:  Cystic fibrosis; respiratory outcomes; social determinants of health; social risk factors; socioeconomic position

Mesh:

Year:  2022        PMID: 35705523      PMCID: PMC9329222          DOI: 10.1080/17476348.2022.2090928

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   4.300


  181 in total

1.  Socioeconomic status, hostility, and risk factor clustering in the Normative Aging Study: any help from the concept of allostatic load?

Authors:  L D Kubzansky; I Kawachi; D Sparrow
Journal:  Ann Behav Med       Date:  1999

2.  Orphan drug pricing and payer management in the United States: are we approaching the tipping point?

Authors:  Rebecca Hyde; Diana Dobrovolny
Journal:  Am Health Drug Benefits       Date:  2010-01

3.  Social complexity negatively influences lung function in cystic fibrosis after transfer to adult care.

Authors:  Erin M Crowley; Gabriel T Bosslet; Babar Khan; Mary Ciccarelli; Cynthia D Brown
Journal:  Pediatr Pulmonol       Date:  2019-09-17

Review 4.  Non-adherence to treatment in cystic fibrosis.

Authors:  B Lask
Journal:  J R Soc Med       Date:  1994       Impact factor: 5.344

5.  Particulate air pollution as a predictor of mortality in a prospective study of U.S. adults.

Authors:  C A Pope; M J Thun; M M Namboodiri; D W Dockery; J S Evans; F E Speizer; C W Heath
Journal:  Am J Respir Crit Care Med       Date:  1995-03       Impact factor: 21.405

6.  A review of cystic fibrosis children born to single mothers.

Authors:  C Macpherson; A O Redmond; A Leavy; M McMullan
Journal:  Acta Paediatr       Date:  1998-04       Impact factor: 2.299

7.  Disparities in Mortality of Hispanic Patients with Cystic Fibrosis in the United States. A National and Regional Cohort Study.

Authors:  Jason Rho; Chul Ahn; Ang Gao; Gregory S Sawicki; Ashley Keller; Raksha Jain
Journal:  Am J Respir Crit Care Med       Date:  2018-10-15       Impact factor: 21.405

Review 8.  Influences of environmental exposures on individuals living with cystic fibrosis.

Authors:  Rhonda Szczesniak; Jessica L Rice; Cole Brokamp; Patrick Ryan; Teresa Pestian; Yizhao Ni; Eleni-Rosalina Andrinopoulou; Ruth H Keogh; Emrah Gecili; Rui Huang; John P Clancy; Joseph M Collaco
Journal:  Expert Rev Respir Med       Date:  2020-04-26       Impact factor: 3.772

9.  Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study.

Authors:  Edward F McKone; Cono Ariti; Abaigeal Jackson; Anna Zolin; Siobhán B Carr; Annalisa Orenti; Jacqui G van Rens; Lydie Lemonnier; Milan Macek; Ruth H Keogh; Lutz Naehrlich
Journal:  Eur Respir J       Date:  2021-10-01       Impact factor: 16.671

10.  International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety.

Authors:  Alexandra L Quittner; Janice Abbott; Anna M Georgiopoulos; Lutz Goldbeck; Beth Smith; Sarah E Hempstead; Bruce Marshall; Kathryn A Sabadosa; Stuart Elborn
Journal:  Thorax       Date:  2015-10-09       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.